Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery
This article was originally published in Start Up
Executive Summary
Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?
You may also be interested in...
Forma To Play To Its Strengths WIth Genentech Deal
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
Forma To Play To Its Strengths WIth Genentech Deal
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.